Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 36 of 36.
Apr 2007
26 Apr · Business
Press release dated April 26, 2007, titled "Zydus Cadila's Net Profit up by whopping 53% in FY 07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Apr · Dividend
Board of Directors in its meeting held on April 26, 2007 have recommended a dividend of Rs.4 (@ 80%) per equity share for the financial year March 31, 2007.20 Apr · Business
Press release dated April 20, 2007, titled "Zydus receives tentative approval for Losartan Potassium tablets". The details of the press release is as follows: "Zydus Cadila has received tentative approval for Losartan Potassium Tablets in the strengths of 25 mg, 50 mg and 100 mg from the USFDA. The branded sales of Losartan Potassium Tablets, which falls in the anti-hypertensive segment, is estimated at USD 817 million in 2006 as per NDC Health. The group now has 23 approvals since the commencement of filing process in FY 2003-04. Currently the group markets 9 generies through its subsidiary Zydus Pharmaceuticals (USA) Inc".19 Apr · Business
"The Company has acquired 100% Stake in Nippon Universal Pharmaceutical Limited, a privately held Company having its headquarter at Tokya, Japan". Further the Company has submitted a copy of the press release dated April 19, 2007, titled "Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Apr · Board meeting
To consider the audited Annual Accounts of the Company for the year ended March 31, 2007 and the Board will consider interalia with other agenda items recommendation of dividend on Equity Shares for the year, 2006 - 07.
Mar 2007
21 Mar · E-mail ID for Investor Complaints
We have created an e-mail ID investor.grievance@zyduscadila.com exclusively for the purpose of registering the complaints by the investor which will be attended by the Company Secretary and Compliance Officer of the Company. Further, we have displayed the above e-mail ID prominently on Company's website to facilitate the Investors to register their grievances directly to the above e-mail ID to ensure the quick response19 Mar · Business
"Company has received three product approvals from USFDA in quick succession to market Azathioprine Tablets 50 mg and tentative approvals for Divalproex Sodium Extended Release Tablets 250 mg and 500 mg and Venlafaxine Hydrochloride Tablets 25mg, 37.5 mg, 50 mg, 75 mg and 100 mg. The Company will market all the three drugs through its US Subsidiary Zydus Pharmaceuticals (USA) Inc". Further the Company has submitted a copy of press release dated March 17, 2007, titled "New Approvals strengthen Zydus' US product basket". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Mar · Business
Press release dated March 16, 2007, titled "Zydus Cadila acquires Liva Healthcare, enters the 1500 cr. derma market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Miscellaneous
Presentation made by the Company's Chairman and Managing Director Mr. Pankaj R Patel at the Sixth Annual 'India Unlimited' Investor Conference in Singapore organized by ICICI Securities on March 05, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12, 2007, titled "Zydus Cadila receives USFDA approval for Paroxetine Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
22 Jan · Business
Press release dated January 22,2007, titled "Zydus Cadila Q3 Net profit up by 66.4%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jan · Board meeting
To consider apart from other agenda items unaudited financial results for the quarter ended on 31st December, 2006.